Diagnostic Array Systems (DAS) has completed a Commercial Ready Grant for the BacTrak System which started in 2007 with funding from AusIndustry.  DAS met its objectives to develop BacTrak a diagnostic genetic microarray for the identification of microbial pathogens causing a range of lung diseases.

The grant in conjunction with BPH Energy funding has assisted in the development of BacTrak which includes a number of key features which underpin its commercial potential. 

These include:

-  Rapid simultaneous detection of 16 respiratory pathogens including Tuberculosis (TB), Legionella and Methycillin resistant Staphylococcus Aureus (MRSA).

-  Results within hours rather than days using the current culture gold standard.

-  Sensitivity and positive confirmation for the 16 pathogens from easily obtained clinical sputum samples.

-  Direct benefits from the project development include:

          -  Earlier, appropriate treatment;

          -  Shorter length of hospital stay;

          -  Earlier potential isolation of hospital patients; and

          -  Reduction in the over-prescription of broad-spectrum antibiotics

The ability of BacTrak to detect respiratory pathogens, including TB, Legionella and MRSA from a single sputum sample is of immense importance and potential value.  Given the global significance and threat of TB in particular it is hoped large volume manufacturing by a suitable IVD manufacturer should deliver a low cost diagnostic kit suitable for deployment in both developing and third world countries

Diagnostic Array Systems also received a Biotechnology Innovation Fund (BIF) grant in 2004 titled 'detecting the cause of infectious diseases using bacterial DNA' which was completed in 2006.

Email Subscription

Enter your email address below to receive our email updates